Akte Therapeutics is developing epigenetic therapies to boost protein production to halt/reverse monogenic diseases. Our platform overcomes the limitations of existing therapeutic approaches to provide treatments for patients in need.
Company Details
- Employees
- 2
- Founded
- -
- Address
- Sydney, Au
- Industry
- Biotechnology Research
- NAICS
-
Research and Development in Biotechnology (except Nanobiotechnology)
- Keywords
- Fontenay-aux-Roses.
- HQ
- Sydney
Akte Therapeutics Questions
Akte Therapeutics's LinkedIn profile is https://au.linkedin.com/company/akte-therapeutics
Akte Therapeutics has
2 employees.
View email and phone details for 2
employees at Akte Therapeutics.
Akte Therapeutics's industry is
Biotechnology Research
Akte Therapeutics's top competitors are
Neuratris,
Provectus Therapeutics,
Organthis,
Levatio Therapeutics,
Korro Bio, Inc.,
Lab-Grown Leather Ltd,
Hongene Biotech Corporation,
The Organoid Company,
St Pharm,
Valley Biosciences.
Akte Therapeutics's categories are Biotechnology Research
Akte Therapeutics's founding year is 2023
